Stoke Therapeutics, Inc. (STOK) Return on equity 2022–2025
Stoke Therapeutics, Inc. (STOK) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-2.0%FY2025 · since FY2022: -54.7% → -2.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -2.0% | +36.9 pp |
| FY2024 | -38.9% | +26.8 pp |
| FY2023 | -65.6% | -10.9 pp |
| FY2022 | -54.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More STOK financial trends
STOK RevenueSTOK Net incomeSTOK Net marginSTOK Gross profitSTOK Gross marginSTOK Operating incomeSTOK Operating marginSTOK Operating cash flowSTOK Free cash flowSTOK Capital expendituresSTOK Stock buybacksSTOK Dividends paidSTOK Total assetsSTOK Total liabilitiesSTOK Shareholders’ equitySTOK overview →